» Articles » PMID: 34335955

Silencing of METTL3 Effectively Hinders Invasion and Metastasis of Prostate Cancer Cells

Overview
Journal Theranostics
Date 2021 Aug 2
PMID 34335955
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

: Since primary prostate cancer (PCa) can advance to the life-threatening metastatic PCa, exploring the molecular mechanisms underlying PCa metastasis is crucial for developing the novel targeted preventive strategies for decreasing the mortality of PCa. RNA N-methyladenosine (mA) is an emerging regulatory mechanism for gene expression and its specific roles in PCa progression remains elusive. Western blotting, quantitative real-time PCR and immunohistochemical analyses were used to detect target gene expression in PCa cells and prostate tissues from patients. RNA immunoprecipitation was conducted to analyze the specific binding of mRNA to the target protein. Migration and invasion assays were used to assess the migratory capacities of cancer cells. The correlation between target gene expression and survival rate of PCa patients was analyzed based the TCGA database. We found that total RNA N-methyladenosine (mA) modification levels were markedly upregulated in human PCa tissues due to increased expression of methyltransferase like 3 (METTL3). Further studies revealed that the migratory and invasive capacities of PCa cells were markedly suppressed upon METTL3 knockdown. Mechanistically, METTL3 mediates mA modification of USP4 mRNA at A2696, and mA reader protein YTHDF2 binds to and induces degradation of mRNA by recruiting RNA-binding protein HNRNPD to the mRNA. Decrease of USP4 fails to remove the ubiquitin group from ELAVL1 protein, resulting in a reduction of ELAVL1 protein. Lastly, downregulation of ELAVL1 in turn increases ARHGDIA expression, promoting migration and invasion of PCa cells. Our findings highlight the role of METTL3 in modulating invasion and metastasis of PCa cells, providing insight into promising therapeutic strategies for hindering PCa progressing to deadly metastases.

Citing Articles

The role of N(6)-methyladenosine (m6a) modification in cancer: recent advances and future directions.

Xie X, Fang Z, Zhang H, Wang Z, Li J, Jia Y EXCLI J. 2025; 24:113-150.

PMID: 39967906 PMC: 11830918. DOI: 10.17179/excli2024-7935.


METTL3: a multifunctional regulator in diseases.

Li N, Wei X, Dai J, Yang J, Xiong S Mol Cell Biochem. 2025; .

PMID: 39853661 DOI: 10.1007/s11010-025-05208-z.


The diverse landscape of RNA modifications in cancer development and progression.

Kim H, Eun J, Jang S, Kim J, Jeong J Genes Genomics. 2024; 47(2):135-155.

PMID: 39643826 DOI: 10.1007/s13258-024-01601-y.


m6A regulator-mediated methylation modifications define the immune infiltration characteristics of the tumor microenvironment in prostate adenocarcinoma.

Jia F, Jing S, Guo J Sci Rep. 2024; 14(1):29047.

PMID: 39580517 PMC: 11585623. DOI: 10.1038/s41598-024-77688-w.


m6A-modified exosome-derived circHIF1α binding to KH domain of IGF2BP3 mediates DNA damage and arrests G1/S transition phase to resists bacterial infection in bacteremia.

Yu J, Gao Y, Liu F, Zhang Y, Li J, Ding L J Nanobiotechnology. 2024; 22(1):654.

PMID: 39443946 PMC: 11515445. DOI: 10.1186/s12951-024-02932-4.


References
1.
Zhang P, He Q, Lei Y, Li Y, Wen X, Hong M . mA-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression. Cell Death Dis. 2018; 9(12):1169. PMC: 6281568. DOI: 10.1038/s41419-018-1224-3. View

2.
Eggener S, Scardino P, Walsh P, Han M, Partin A, Trock B . Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011; 185(3):869-75. PMC: 4058776. DOI: 10.1016/j.juro.2010.10.057. View

3.
Song H, Feng X, Zhang H, Luo Y, Huang J, Lin M . METTL3 and ALKBH5 oppositely regulate mA modification of mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes. Autophagy. 2019; 15(8):1419-1437. PMC: 6613905. DOI: 10.1080/15548627.2019.1586246. View

4.
Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

5.
Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M . The mA methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene. 2019; 38(19):3667-3680. DOI: 10.1038/s41388-019-0683-z. View